Autolus Therapeutics plc Logo

Autolus Therapeutics plc

AUTL

(0.8)
Stock Price

3,08 USD

-27.41% ROA

-66.76% ROE

-4.62x PER

Market Cap.

1.080.145.006,00 USD

46.02% DER

0% Yield

-1906.63% NPM

Autolus Therapeutics plc Stock Analysis

Autolus Therapeutics plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Autolus Therapeutics plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (22%), which means it has a small amount of debt compared to the ownership it holds

2 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-64.88%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-34.39%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (3.37x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Autolus Therapeutics plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Autolus Therapeutics plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Autolus Therapeutics plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Autolus Therapeutics plc Revenue
Year Revenue Growth
2015 94.112
2016 1.212.000 92.23%
2017 1.693.000 28.41%
2018 1.045.343 -61.96%
2019 2.908.000 64.05%
2020 242.000 -1101.65%
2021 2.330.000 89.61%
2022 6.194.000 62.38%
2023 1.624.000 -281.4%
2023 1.698.000 4.36%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Autolus Therapeutics plc Research and Development Expenses
Year Research and Development Expenses Growth
2015 2.172.614
2016 10.436.000 79.18%
2017 16.012.000 34.82%
2018 24.637.550 35.01%
2019 105.418.000 76.63%
2020 134.888.000 21.85%
2021 134.789.000 -0.07%
2022 141.992.000 5.07%
2023 148.948.000 4.67%
2023 130.481.000 -14.15%
2024 146.448.000 10.9%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Autolus Therapeutics plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 6.043.960
2016 5.152.000 -17.31%
2017 9.099.000 43.38%
2018 16.845.786 45.99%
2019 39.452.000 57.3%
2020 34.972.000 -12.81%
2021 31.865.000 -9.75%
2022 31.899.000 0.11%
2023 42.444.000 24.84%
2023 46.745.000 9.2%
2024 87.612.000 46.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Autolus Therapeutics plc EBITDA
Year EBITDA Growth
2015 -4.470.167
2016 -13.898.000 67.84%
2017 -22.409.000 37.98%
2018 -35.209.006 36.35%
2019 -133.249.000 73.58%
2020 -162.487.000 17.99%
2021 -155.749.000 -4.33%
2022 -156.363.000 0.39%
2023 -176.056.000 11.19%
2023 -188.463.000 6.58%
2024 -226.480.000 16.79%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Autolus Therapeutics plc Gross Profit
Year Gross Profit Growth
2015 94.112
2016 734.000 87.18%
2017 684.001 -7.31%
2018 -47.253.657 101.45%
2019 -1.703.000 -2674.73%
2020 -134.646.000 98.74%
2021 -126.321.000 -6.59%
2022 -131.026.000 3.59%
2023 96.000 136585.42%
2023 -4.867.000 101.97%
2024 -7.580.000 35.79%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Autolus Therapeutics plc Net Profit
Year Net Profit Growth
2015 -7.464.150
2016 -12.550.000 40.52%
2017 -19.727.000 36.38%
2018 -31.114.488 36.6%
2019 -123.849.000 74.88%
2020 -142.094.000 12.84%
2021 -142.096.000 0%
2022 -148.839.000 4.53%
2023 -183.396.000 18.84%
2023 -208.383.000 11.99%
2024 -233.088.000 10.6%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Autolus Therapeutics plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -1
2016 -1 0%
2017 -1 100%
2018 -1 0%
2019 -3 100%
2020 -3 0%
2021 -2 -100%
2022 -2 0%
2023 -1 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Autolus Therapeutics plc Free Cashflow
Year Free Cashflow Growth
2015 -4.087.521
2016 -11.704.000 65.08%
2017 -19.236.000 39.16%
2018 -34.618.709 44.43%
2019 -120.152.000 71.19%
2020 -132.439.000 9.28%
2021 -126.718.000 -4.51%
2022 -123.149.000 -2.9%
2023 -156.573.000 21.35%
2023 -41.686.000 -275.6%
2024 -51.923.999 19.72%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Autolus Therapeutics plc Operating Cashflow
Year Operating Cashflow Growth
2015 -3.325.456
2016 -9.849.000 66.24%
2017 -16.360.000 39.8%
2018 -25.847.353 36.71%
2019 -101.484.000 74.53%
2020 -117.758.000 13.82%
2021 -117.861.000 0.09%
2022 -112.308.000 -4.94%
2023 -145.587.000 22.86%
2023 -40.188.000 -262.26%
2024 -51.082.999 21.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Autolus Therapeutics plc Capital Expenditure
Year Capital Expenditure Growth
2015 762.065
2016 1.855.000 58.92%
2017 2.876.000 35.5%
2018 8.771.356 67.21%
2019 18.668.000 53.01%
2020 14.681.000 -27.16%
2021 8.857.000 -65.76%
2022 10.841.000 18.3%
2023 10.986.000 1.32%
2023 1.498.000 -633.38%
2024 841.000 -78.12%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Autolus Therapeutics plc Equity
Year Equity Growth
2015 20.706.907
2016 30.687.000 32.52%
2017 142.601.000 78.48%
2018 205.139.436 30.49%
2019 254.839.000 19.5%
2020 210.032.000 -21.33%
2021 313.320.000 32.97%
2022 298.674.000 -4.9%
2023 111.474.000 -167.93%
2023 180.518.000 38.25%
2024 527.844.000 65.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Autolus Therapeutics plc Assets
Year Assets Growth
2015 22.655.233
2016 34.180.000 33.72%
2017 148.662.000 77.01%
2018 217.656.705 31.7%
2019 303.533.000 28.29%
2020 294.237.000 -3.16%
2021 405.560.000 27.45%
2022 490.274.000 17.28%
2023 375.381.000 -30.61%
2023 406.098.000 7.56%
2024 853.620.000 52.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Autolus Therapeutics plc Liabilities
Year Liabilities Growth
2015 1.948.325
2016 3.493.000 44.22%
2017 6.061.000 42.37%
2018 12.517.269 51.58%
2019 48.694.000 74.29%
2020 84.205.000 42.17%
2021 92.240.000 8.71%
2022 191.600.000 51.86%
2023 263.906.999 27.4%
2023 225.580.000 -16.99%
2024 325.776.000 30.76%

Autolus Therapeutics plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.05
Net Income per Share
-0.88
Price to Earning Ratio
-4.62x
Price To Sales Ratio
88.02x
POCF Ratio
-6.9
PFCF Ratio
-6.71
Price to Book Ratio
2.05
EV to Sales
53.93
EV Over EBITDA
-3.75
EV to Operating CashFlow
-4.23
EV to FreeCashFlow
-4.11
Earnings Yield
-0.22
FreeCashFlow Yield
-0.15
Market Cap
1,08 Bil.
Enterprise Value
0,66 Bil.
Graham Number
6.27
Graham NetNet
1.54

Income Statement Metrics

Net Income per Share
-0.88
Income Quality
0.67
ROE
-0.67
Return On Assets
-0.27
Return On Capital Employed
-0.23
Net Income per EBT
1.03
EBT Per Ebit
1.22
Ebit per Revenue
-15.19
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
5.41
Research & Developement to Revenue
10.57
Stock Based Compensation to Revenue
0.93
Gross Profit Margin
0.52
Operating Profit Margin
-15.19
Pretax Profit Margin
-18.46
Net Profit Margin
-19.07

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.59
Free CashFlow per Share
-0.61
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.35
Capex to Depreciation
0.63
Return on Invested Capital
-0.25
Return on Tangible Assets
-0.27
Days Sales Outstanding
1102.14
Days Payables Outstanding
68.41
Days of Inventory on Hand
0
Receivables Turnover
0.33
Payables Turnover
5.34
Inventory Turnover
0
Capex per Share
0.02

Balance Sheet

Cash per Share
2,66
Book Value per Share
1,98
Tangible Book Value per Share
1.98
Shareholders Equity per Share
1.98
Interest Debt per Share
1.16
Debt to Equity
0.46
Debt to Assets
0.28
Net Debt to EBITDA
2.37
Current Ratio
18.5
Tangible Asset Value
0,53 Bil.
Net Current Asset Value
0,43 Bil.
Invested Capital
806452000
Working Capital
0,72 Bil.
Intangibles to Total Assets
0
Average Receivables
0,03 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.22

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Autolus Therapeutics plc Dividends
Year Dividends Growth

Autolus Therapeutics plc Profile

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

CEO
Dr. Christian Martin Itin Ph.D
Employee
463
Address
The MediaWorks
London, W12 7FP

Autolus Therapeutics plc Executives & BODs

Autolus Therapeutics plc Executives & BODs
# Name Age
1 Mr. Brent Rice
Senior Vice President, Chief Commercial Officer & Site Head of US
70
2 Ms. Olivia Manser
Director of Investor Relations
70
3 Dr. Chris Williams
Senior Vice President & Chief Business Development Officer
70
4 Mr. Alexander Swan
Senior Vice President & Chief Human Resources Officer
70
5 Mr. Alex Driggs
Senior Vice President of Legal Affairs & General Counsel and Secretary
70
6 Mr. Robert F. Dolski
Senior Vice President & Chief Financial Officer
70
7 Dr. Christian Martin Itin Ph.D.
Chief Executive Officer & Director
70
8 Dr. Martin Pule M.D., MBBS
Founder, Senior Vice President & Chief Scientific Officer
70
9 Mr. Christopher Vann
Senior Vice President & Chief Operating Officer
70
10 Mr. David Brochu
Senior Vice President & Chief Technical Officer
70

Autolus Therapeutics plc Competitors